Summary
7.56 -0.10(-1.31%)07/05/2024
AxoGen Inc (AXGN)
AxoGen Inc (AXGN)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -0.53 | 5.00 | 8.00 | -3.08 | -11.58 | -11.99 | -61.99 | 132.23 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 7.56 | |
| Open | 7.63 | |
| High | 7.71 | |
| Low | 7.35 | |
| Volume | 160,383 | |
| Change | -0.04 | |
| Change % | -0.53 | |
| Avg Volume (20 Days) | 294,778 | |
| Volume/Avg Volume (20 Days) Ratio | 0.54 | |
| 52 Week Range | 3.45 - 10.83 | |
| Price vs 52 Week High | -30.19% | |
| Price vs 52 Week Low | 119.13% | |
| Range | -0.92 | |
| Gap Up/Down | -0.03 | |
Fundamentals | ||
| Market Capitalization (Mln) | 330 | |
| EBIDTA | -13,388,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 12.67 | |
| Book Value | 2.1320 | |
| Earnings Per Share | -0.4900 | |
| EPS Estimate Current Quarter | -0.0700 | |
| EPS Estimate Next Quarter | -0.0500 | |
| EPS Estimate Current Year | -0.1300 | |
| EPS Estimate Next Year | 0.1700 | |
| Diluted EPS (TTM) | -0.4900 | |
| Revenues | ||
| Profit Marging | -0.1300 | |
| Operating Marging (TTM) | -0.1102 | |
| Return on asset (TTM) | -0.0621 | |
| Return on equity (TTM) | -0.2232 | |
| Revenue TTM | 163,726,000 | |
| Revenue per share TTM | 3.8040 | |
| Quarterly Revenue Growth (YOY) | 0.1290 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 114,437,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 3.2949 | |
| Revenue Enterprise Value | 2.2229 | |
| EBITDA Enterprise Value | -26.5212 | |
| Shares | ||
| Shares Outstanding | 43,704,600 | |
| Shares Float | 33,867,548 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.05 | |
| Insider (%) | 5.22 | |
| Institutions (%) | 75.61 | |
07/01 07:00 EST - globenewswire.com
Company Reports Inducement Grants to Non-Executive New Employee Under Nasdaq Listing Rule 5635(C)(4)
ALACHUA, Fla. and TAMPA, Fla., July 01, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced making an inducement grant on July 1, 2024, under NASDAQ listing rule 5635(c)(4) in connection with the hire of a new non-executive employee.
Company Reports Inducement Grants to Non-Executive New Employee Under Nasdaq Listing Rule 5635(C)(4)
ALACHUA, Fla. and TAMPA, Fla., July 01, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced making an inducement grant on July 1, 2024, under NASDAQ listing rule 5635(c)(4) in connection with the hire of a new non-executive employee.
06/25 13:55 EST - zacks.com
AxoGen's (AXGN) New Launch to Aid Peripheral Nerve Protection
AxoGen (AXGN) announces the full launch of its Avive+ Soft Tissue Matrix to provide comprehensive solutions for nerve protection.
AxoGen's (AXGN) New Launch to Aid Peripheral Nerve Protection
AxoGen (AXGN) announces the full launch of its Avive+ Soft Tissue Matrix to provide comprehensive solutions for nerve protection.
06/24 07:00 EST - globenewswire.com
Axogen, Inc Announces Full Launch of Avive+ Soft Tissue Matrix™
ALACHUA, Fla. and TAMPA, Fla., June 24, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announces the launch of its newest product, Avive+ Soft Tissue Matrix™. Avive+™ is intended for use as a soft tissue barrier and is a resorbable, multi-layer amniotic membrane allograft that provides temporary protection and tissue separation during the critical phase of peripheral nerve healing. Avive+ is processed and distributed in accordance with U.S. Food and Drug Administration (FDA) requirements for Human Cellular and Tissue-based Products (HCT/P) under 21 CFR Part 1271 regulations, U.S. State regulations as a 361 human tissue product.
Axogen, Inc Announces Full Launch of Avive+ Soft Tissue Matrix™
ALACHUA, Fla. and TAMPA, Fla., June 24, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announces the launch of its newest product, Avive+ Soft Tissue Matrix™. Avive+™ is intended for use as a soft tissue barrier and is a resorbable, multi-layer amniotic membrane allograft that provides temporary protection and tissue separation during the critical phase of peripheral nerve healing. Avive+ is processed and distributed in accordance with U.S. Food and Drug Administration (FDA) requirements for Human Cellular and Tissue-based Products (HCT/P) under 21 CFR Part 1271 regulations, U.S. State regulations as a 361 human tissue product.
06/12 06:01 EST - zacks.com
Strength Seen in AxoGen (AXGN): Can Its 5.4% Jump Turn into More Strength?
AxoGen (AXGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Strength Seen in AxoGen (AXGN): Can Its 5.4% Jump Turn into More Strength?
AxoGen (AXGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
05/28 16:30 EST - globenewswire.com
Axogen Processing Center (APC) Celebrates its Opening with Ohio Leaders in Vandalia
Showcasing Axogen's Dedication to Fueling Ohio's Biotechnology Sector Growth Showcasing Axogen's Dedication to Fueling Ohio's Biotechnology Sector Growth
Axogen Processing Center (APC) Celebrates its Opening with Ohio Leaders in Vandalia
Showcasing Axogen's Dedication to Fueling Ohio's Biotechnology Sector Growth Showcasing Axogen's Dedication to Fueling Ohio's Biotechnology Sector Growth
05/17 13:31 EST - zacks.com
AxoGen (AXGN) Initiates BLA Submission for Avance Nerve Graft
AxoGen (AXGN) starts the process of BLA submission to the FDA for the approval of its Avance Nerve Graft.
AxoGen (AXGN) Initiates BLA Submission for Avance Nerve Graft
AxoGen (AXGN) starts the process of BLA submission to the FDA for the approval of its Avance Nerve Graft.
05/05 01:21 EST - seekingalpha.com
AxoGen, Inc. (AXGN) Q1 2024 Earnings Call Transcript
AxoGen, Inc. (NASDAQ:AXGN ) Q1 2024 Earnings Conference Call May 2, 2024 8:00 AM ET Company Participants Harold Tamayo - VP, Finance and IR Karen Zaderej - Chairman, CEO and President Nir Naor - CFO Conference Call Participants Michael Sarcone - Jefferies Mike Kratky - Leerink Partners Caitlin Cronin - Canaccord Genuity Ross Osborn - Cantor Fitzgerald Operator Greetings, and welcome to the AxoGen, Inc. 2024 First Quarter Financial Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded.
AxoGen, Inc. (AXGN) Q1 2024 Earnings Call Transcript
AxoGen, Inc. (NASDAQ:AXGN ) Q1 2024 Earnings Conference Call May 2, 2024 8:00 AM ET Company Participants Harold Tamayo - VP, Finance and IR Karen Zaderej - Chairman, CEO and President Nir Naor - CFO Conference Call Participants Michael Sarcone - Jefferies Mike Kratky - Leerink Partners Caitlin Cronin - Canaccord Genuity Ross Osborn - Cantor Fitzgerald Operator Greetings, and welcome to the AxoGen, Inc. 2024 First Quarter Financial Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded.
05/02 09:16 EST - zacks.com
AxoGen (AXGN) Reports Q1 Loss, Lags Revenue Estimates
AxoGen (AXGN) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.10 per share a year ago.
AxoGen (AXGN) Reports Q1 Loss, Lags Revenue Estimates
AxoGen (AXGN) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.10 per share a year ago.
05/02 07:00 EST - globenewswire.com
Axogen, Inc Reports First Quarter 2024 Financial Results
ALACHUA, Fla. and TAMPA, Fla., May 02, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the first quarter ended March 31, 2024.
Axogen, Inc Reports First Quarter 2024 Financial Results
ALACHUA, Fla. and TAMPA, Fla., May 02, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the first quarter ended March 31, 2024.
04/29 16:50 EST - globenewswire.com
Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix™
ALACHUA, Fla. and TAMPA, Fla., April 29, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announces the first surgical implantations of its newest product, Avive+ Soft Tissue Matrix™.
Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix™
ALACHUA, Fla. and TAMPA, Fla., April 29, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announces the first surgical implantations of its newest product, Avive+ Soft Tissue Matrix™.
04/16 07:00 EST - globenewswire.com
Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
ALACHUA, Fla. and TAMPA, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report first quarter 2024 financial results on Thursday, May 2, 2024, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release.
Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
ALACHUA, Fla. and TAMPA, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report first quarter 2024 financial results on Thursday, May 2, 2024, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release.
03/05 11:03 EST - seekingalpha.com
AxoGen, Inc. (AXGN) Q4 2023 Earnings Call Transcript
AxoGen, Inc. (NASDAQ:AXGN ) Q4 2023 Earnings Call Transcript March 5, 2024 8:00 AM ET Company Participants Harold Tamayo - VP, Finance and IR Karen Zaderej - Chairman, CEO and President Nir Naor - CFO Conference Call Participants Chris Pasquale - Nephron Mike Sarcone - Jefferies Mike Kratky - Leerink Partners Caitlin Cronin - Canaccord Genuity Dave Turkaly - Citizens JMP Ross Osborn - Cantor Fitzgerald Operator Hello, and welcome to the AxoGen, Inc. 2023 Fourth Quarter and Full Year Financial Results Conference Call and Webcast. [Operator Instructions] As a reminder, this conference is being recorded.
AxoGen, Inc. (AXGN) Q4 2023 Earnings Call Transcript
AxoGen, Inc. (NASDAQ:AXGN ) Q4 2023 Earnings Call Transcript March 5, 2024 8:00 AM ET Company Participants Harold Tamayo - VP, Finance and IR Karen Zaderej - Chairman, CEO and President Nir Naor - CFO Conference Call Participants Chris Pasquale - Nephron Mike Sarcone - Jefferies Mike Kratky - Leerink Partners Caitlin Cronin - Canaccord Genuity Dave Turkaly - Citizens JMP Ross Osborn - Cantor Fitzgerald Operator Hello, and welcome to the AxoGen, Inc. 2023 Fourth Quarter and Full Year Financial Results Conference Call and Webcast. [Operator Instructions] As a reminder, this conference is being recorded.
03/05 07:00 EST - globenewswire.com
Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results
ALACHUA, Fla. and TAMPA, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the fourth quarter and full-year ended December 31, 2023.
Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results
ALACHUA, Fla. and TAMPA, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the fourth quarter and full-year ended December 31, 2023.
03/04 08:06 EST - zacks.com
4 Must-Buy Stocks for Remarkable Earnings Acceleration
Some of the notable companies to have witnessed solid earnings acceleration as of now are Protagonist Therapeutics (PTGX), AxoGen (AXGN), Western Digital (WDC) and Phunware (PHUN).
4 Must-Buy Stocks for Remarkable Earnings Acceleration
Some of the notable companies to have witnessed solid earnings acceleration as of now are Protagonist Therapeutics (PTGX), AxoGen (AXGN), Western Digital (WDC) and Phunware (PHUN).
02/28 09:51 EST - zacks.com
AxoGen (AXGN) Is a Great Choice for 'Trend' Investors, Here's Why
AxoGen (AXGN) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
AxoGen (AXGN) Is a Great Choice for 'Trend' Investors, Here's Why
AxoGen (AXGN) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
02/26 10:16 EST - zacks.com
AxoGen, Inc. (AXGN) Hit a 52 Week High, Can the Run Continue?
AxoGen (AXGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
AxoGen, Inc. (AXGN) Hit a 52 Week High, Can the Run Continue?
AxoGen (AXGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
02/16 07:11 EST - zacks.com
3 Best Stocks to Buy for Remarkable Earnings Acceleration
Invest in stocks such as AxoGen (AXGN), Western Digital (WDC) and Gen Digital (GEN) as of now for superb earnings acceleration.
3 Best Stocks to Buy for Remarkable Earnings Acceleration
Invest in stocks such as AxoGen (AXGN), Western Digital (WDC) and Gen Digital (GEN) as of now for superb earnings acceleration.
02/13 16:30 EST - globenewswire.com
Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024
ALACHUA, Fla. and TAMPA, Fla., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report 2023 fourth quarter and full-year financial results on Tuesday, March 5, 2024, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release.
Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024
ALACHUA, Fla. and TAMPA, Fla., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report 2023 fourth quarter and full-year financial results on Tuesday, March 5, 2024, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release.
02/12 09:51 EST - zacks.com
Here's Why Momentum in AxoGen (AXGN) Should Keep going
If you are looking for stocks that are well positioned to maintain their recent uptrend, AxoGen (AXGN) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Here's Why Momentum in AxoGen (AXGN) Should Keep going
If you are looking for stocks that are well positioned to maintain their recent uptrend, AxoGen (AXGN) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
02/06 10:42 EST - zacks.com
Is AxoGen (AXGN) Stock Outpacing Its Medical Peers This Year?
Here is how AxoGen (AXGN) and Boston Scientific (BSX) have performed compared to their sector so far this year.
Is AxoGen (AXGN) Stock Outpacing Its Medical Peers This Year?
Here is how AxoGen (AXGN) and Boston Scientific (BSX) have performed compared to their sector so far this year.